Long-Term Prognosis of Antimelanoma Differentiation–Associated Gene 5–Positive Dermatomyositis With Interstitial Lung Disease
Authors' conclusion
Triple combination therapy in the induction phase can reduce the risk of recurrence and facilitate drug withdrawal in anti-MDA5-positive DM-ILD.
Study context
- Population
- Patients with anti-MDA5-positive dermatomyositis with interstitial lung disease (DM-ILD) from a previous multicentre trial plus 73 other patients from the authors' institute; those who achieved remission and survived > 6 monthsachieved remission, survived > 6 months
- Participants
- 68 patients
- Comparison
- Triple combination induction therapy vs monotherapy/dual therapy
- Group Tn = 56
- Group Cn = 12reference
- Primary endpoint
- Recurrence-free rate and drug-withdrawal rates of immunosuppressive agents
Methodological detailsretrospective integration of institutional cohort, follow-up > 5 years
- Retrospective integration of institutional cohort
- Follow-up > 5 years
Primary result
As reported in the abstract
Recurrence-free rate
P < 0.05
Further findings
CNI withdrawal rate · 10 years
P < 0.05
GC withdrawal rate · 10 years
P < 0.05
Overall survival and recurrence-free survival, previous trial participants · 5 years
- Overall survival and recurrence-free survival rates
- 100%
Cumulative withdrawal rates, previous trial participants · 5 years
- CNI withdrawal
- 70%
- GC withdrawal
- 53%
Original publication
Long-Term Prognosis of Antimelanoma Differentiation–Associated Gene 5–Positive Dermatomyositis With Interstitial Lung Disease. J Rheumatol. Published 15 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →